Co-Organized by the Catalan Institute of Oncology (ICO), the Program Against Therapeutic Resistance (ProCURE), and Vall d´Hebron Institute of Oncology (VHIO), Cancer Therapeutic Resistance: Progress and Perspectives, 07 – 08 April 2016, celebrated at the CosmoCaixa Science Museum of the Fundació Bancària “la Caixa” in Barcelona, provided us all with unparalleled opportunity to collectively discuss and debate the very latest insights aimed at tackling THE major obstacle in combating cancer: resistance to anti-cancer therapies.
Thanks to the superb co-chairmanship of Miguel Angel Pujana (ProCURE, ICO), and Joaquín Arribas (VHIO), coupled with an outstanding panel of world-class speakers, we were able to exchange expertise and explore experiences from a variety of different perspectives at preclinical, translational, and clinical research levels.
More specifically, through the especially selected six core Sessions – Immunology & Cancer Therapy, Genetics, Epigenetics & Mechanisms, Molecular Classification & Therapeutic Targeting, Cancer Omics & Therapeutics, Molecular Signaling & Models, and Stem Cells & Malignization, this two-day meeting highlighted both the opportunities and current challenges surrounding novel strategies and approaches that promise to overcome drug resistance and counteract tumor cell spread factors through the development of more effective and precise targeted therapies.
Just some of the many must-have conversations centered on and around the application and extension of immunotherapies to different tumor types, the cancer genome and epigenome and how latest data is being applied to advance cancer detection, monitoring and therapy, as well as current therapeutic strategies matched to molecular subtypes of disease and new avenues for molecularly targeted therapy against metastatic disease.
We were also updated on the latest translation of cancer ´omic´intelligence into accelerated development and application of personalized cancer medicine, explored current preclinical models and programs that track cancer progression and predict response to anti-cancer drugs, as well as insights into the development of therapies and approaches targeted at CSCs in order to better forecast outcomes and checkmate therapeutic resistance.
In short, this first-class B-Debate meeting represented an important next step in our determined efforts to reverse cancer drug resistance — getting smarter and moving faster in our collective quest to conquer cancer.
To discover more about the many highlights, view the photo gallery, as well as download the meeting Synopsis, please visit: